AstraZeneca bags another US indication for Ultomiris with IgAN approval
Article excerpt
Highlighted: the sentence this signal was extracted from
AstraZeneca has notched another indication to the belt of its rare disease therapy Ultomiris (ravulizumab) through an accelerated US approval in primary immunoglobulin A nephropathy (IgAN), a type of chronic kidney disease. Following the US Food and Drug Administration's (FDA) call to initially greenlight Ultomiris in IgAN, the drug will provisionally be available to patients at risk of disease progression – specifically to reduce the presence of protein in the urine. The gold standard of business intelligence. Find out more Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms. Find out more Ultomiris' accelerated approval stems from the Phase III I CAN trial (NCT06291376) in which the intravenously delivered C5 complement inhibitor prompted a placebo-adjusted 43.4% drop in the presence of excess urine proteins in IgAN patients at the 34-week mark. While the drug has already shown promise in reducing proteinuria, AstraZeneca is yet to establish whether Ultomiris can slow the functional decline of kidneys in IgAN patients. This means that Ultomiris' full US approval in IgAN will hinge on whether the drug can demonstrate clinical benefit in the ongoing Phase III I CAN trial, in which researchers are evaluating the drug's impact on the rate at which the kidneys filter blood. IgAN is a rare, progressive kidney...
Keep reading with a free account
The rest of this article, and every signal for AstraZeneca, is in your free account.
